Contineum Therapeutics, Inc. (CTNM) Stock Price & Analysis
Contineum Therapeutics, Inc. (CTNM) fell 4.95% to USD 16.7 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.
CTNM last closed at USD 16.7; the session ranged USD 16.5–17.71 on volume of 346,230 shares. Market capitalization is —, with a 52-week range of USD 8.6–17.79 (NMS). Source: Nexqual, September 8, 2026 at 07:36 UTC.
Key Statistics (as of September 8, 2026 at 07:36 UTC)
| Price | USD 16.7 |
|---|---|
| Change | ▼ 4.95% (down) |
| Previous Close | USD 16.7 |
| Open | USD 16.7 |
| Day Range | USD 16.5 – 17.71 |
| 52-Week Range | USD 8.6 – 17.79 |
| Volume | 346,230 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (CTNM)
Nexqual's technical model rates CTNM "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.73 (neutral) |
| vs SMA50 | Above (USD 15.35) |
| MACD | 0.6 (positive) |
From Contineum Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- We have built our current pipeline with the goal of minimizing clinical risk.
- Our collaboration provides a foundation for the development of PIPE-307 with access to J&J's robust R&D and commercialization capabilities, which we believe will allow us to achieve the full potential of PIPE-307.
- CTX-343 In addition to PIPE-791, our brain penetrant drug candidate, we have developed CTX-343, a peripherally-restricted LPA1R antagonist, to potentially expand clinical indications involving LPA1R antagonism.
- To that end, we have developed a selective calpain inhibitor which was recently moved into preclinical studies.
Partnerships
- We recognize that partnerships may provide a more prudent development path in certain cases to reduce costs and accelerate the delivery of effective therapies to market, as exemplified by our partnership with J&J.
- In February 2023, we entered into a license agreement with J&J, under which we granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications ("J&J License Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | USD 30.95 | ▲ 1.44% |
| RAPP | Rapport Therapeutics, Inc. | USD 45.77 | ▼ 6% |
| ANRO | Alto Neuroscience, Inc. | USD 35.55 | ▼ 2.97% |
| BCAX | Bicara Therapeutics Inc. | USD 23.17 | ▼ 1.66% |
| UPB | Upstream Bio, Inc. | USD 6.01 | ▼ 7.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.